Pacgen Life Science Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2015. For the quarter, the company reported revenue was CAD 16,691,000 compared to CAD 14,197,000 a year ago. Net loss and comprehensive loss for the period was CAD 2,996,000 compared to net income and comprehensive income for the period of CAD 7,195,000 a year ago.

For the nine months, the company reported revenue was CAD 48,425,000 compared to CAD 44,038,000 a year ago. Net income and comprehensive income for the period was CAD 6,597,000 compared to CAD 12,627,000 a year ago. Cash provided by operating activities was CAD 10,871,000 compared to cash used in operating activities of CAD 53,766,000 a year ago.